ADVANCED NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on tough lung cancer
Disease control Not yet recruitingThis study is testing if adding targeted local treatments like radiation or surgery to the drug lorlatinib helps people with advanced ALK-positive lung cancer live longer without their cancer getting worse. It will involve about 30 adults who have not taken certain other targeted…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis study is testing whether adding a new drug called capivasertib to a standard lung cancer drug (osimertinib) can help control advanced non-small cell lung cancer that has specific genetic changes and has started growing again after initial treatment. It will involve about 53 …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New blood test could be key to personalizing lung cancer care
Knowledge-focused Not yet recruitingThis study aims to find out if a new blood test can predict which patients with advanced lung cancer will respond best to a standard combination of chemotherapy and immunotherapy. Researchers will measure specific immune cells in the blood of 80 patients before and during treatme…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:28 UTC